<DOC>
	<DOCNO>NCT01350154</DOCNO>
	<brief_summary>This study do evaluate whether treatment drug sildenafil ( RevatioÂ® ) improve muscular , cardiac , cerebrovascular cognitive function patient Beckers muscular dystrophy compare placebo ( inactive medication ) . The study base recent finding improve cardiac function mouse model muscular dystrophy ( Adamo et al 2010 ) previous finding change cognitive function people Becker dystrophy . In muscular dystrophy , cellular protein , dystrophin affect . During normal condition , enzyme neuronal nitric oxide synthase ( nNOS ) , produce nitric oxide ( NO ) , attach dystrophin . NO important normal vascular function muscle , heart brain stimulating production cyclic GMP . However , muscular dystrophy dystrophin deficiency , nNOS normal cellular anchor , result decrease NO level subsequent reduce cyclic GMP production . Sildenafil inhibit degradation cGMP thus prolong increase cGMP response . Such effect basis use sildenafil pulmonary hypertension erectile dysfunction . Current hypothesis : Sildenafil restore cyclic GMP function affect muscular dystrophy wit nNOS deficiency result improved muscle , cardiac , cerebrovascular cognitive function .</brief_summary>
	<brief_title>Effect Modulating nNOS System Cardiac , Muscular Cognitive Function Becker Muscular Dystrophy Patients</brief_title>
	<detailed_description>The current clinical trial include people Becker 's muscular dystrophy establish deficiency muscular content nNOS protein consist three sub-studies focus muscle function , cardiac function brain function . In muscular dystrophy dystrophin cellular complex usually locate muscle cell , disrupt result know reduced nNOS activity . The reduced nNOS lead reduce cyclic GMP production . nNOS cyclic GMP involve vascular response striate muscle , cardiac vessel well cerebrovascular response hypercapnia regional activation . In muscular dystrophy , affect muscular cardiac function patient change cognitive function describe . Whether relate reduced nNOS function subsequent cGMP production fully understood . Inhibition cGMP degradation inhibit cGMP degrade enzyme phosphodiesterase 5 ( PDE5 ) use PDE5 inhibitor sildenafil may result restoration vascular response . The study design double blind , randomise , balance , placebo-controlled cross-over study perform 10 week treatment period . The patient receive 4 week either sildenafil placebo 2 week washout period treatment . The study out-come parameter perform two consecutive day baseline , 4 week 10 week , two collaborating center , Rigshospitalet muscle cardiac parameter Glostrup Hospital cerebrovascular cognitive parameter . The primary endpoint relate sub-study , assess compare individual change baseline placebo/sildenafil treatment .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Muscular dystrophy know deficiency nNOS Reduced cardiac function ( &lt; 50 % ) and/or reduce muscular function ( MRC &lt; 4+ ) Stable dosing ( &gt; 3 month ) cardiovascular medication Signed informed consent Recent ( &lt; 6 month ) cerebral cardiac stroke Use nitrate contain compound , alpha receptor block agent potent CUP3A4 inhibitor . Intolerance allergy sildenafil , intake drug compatible sildenafil intake Overuse drug alcohol inclusion trial experimental medication within last 30 day know epilepsy reduce liver function ( ASAT &gt; 500U/l 2 repeat measurement correct increase creatinkinase level . nonarteriitis anterior ischemic optic neuropathy ( NAION ) reduce vision contraindication MRI scan ( metal implant , claustrophobia ) hypotension ( &lt; 90 mmHg systolic baseline ) condition , medical psychosocial make subject inclusion inadvisable</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>sildenafil</keyword>
	<keyword>revatio</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>adult</keyword>
	<keyword>nNOS</keyword>
</DOC>